Waratah Pharmaceuticals, Inc.
|Waratah Pharmaceuticals, Inc. Patent applications|
|Patent application number||Title||Published|
|20140155480||Scyllo-Inositol Derivatives and Their Use in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation of Amyloid Formation, Deposition, Accumulation for Persistence - Scyllo-Inositol derivatives represented by structural formula II are described, wherein at least one and not more than five of R||06-05-2014|
|20140135403||USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF OCULAR DISEASES - The present invention relates to methods of treating ocular diseases in a subject by administering to the subject a therapeutically effective amount of one or more cyclohexanehexyl derivatives, or salts thereof, or a medicament comprising a cyclohexanehexol derivative and a pharmaceutically acceptable carrier. More specifically, the invention provides a medicament comprising at least one cyclohexanehexyl derivative of formula (III) or (IV) useful in preventing or treating ocular diseases, by modulating the folding, oligomerization or aggregation of amyloid β in ocular cells. Methods of administration of these medicaments include systemic, transpleural, oral, intravenously, intraarterial, intramuscular, topical, via inhalation, transdermal, subcutaneous, intraperitoneal, gastrointestinal, and directly to the eye or tissues surrounding the eyes. Formulae (III), (IV).||05-15-2014|
|20110034379||Gastrin Compositions And Formulations, And Methods Of Use And Preparation - An embodiment of the invention provided herein is a pharmaceutical composition comprising a gastrin compound having an extended activity upon administration to a subject in comparison with native gastrin. Methods are provided of conjugating portions of the amino acid sequence of gastrin having functional ability to bind to the gastrin/CCK receptor, to various carrier moieties, including the use of amino acid spacer regions, and use of bifunctional cross-linking reagents. Methods of treating a diabetes patient with the compositions are provided.||02-10-2011|
|20090269337||COMPOSITIONS AND METHODS FOR TREATING DIABETES - Compositions and methods for islet neogenesis therapy comprising an EGF and a gastrin in combination with immune suppression, and for treating or preventing early stage diabetes with a gastrin/CCK receptor ligand and an immunosuppressant are provided.||10-29-2009|
|20090036381||TREATMENT OF DIABETES - Compositions and methods are provided for islet neogenesis therapy comprising a member of a group of factors that complement a gastrin/CCK receptor ligand, with formulations, devices and methods for sustained release delivery and for local delivery to target organs.||02-05-2009|
Patent applications by Waratah Pharmaceuticals, Inc.